Also, our in silico analysis showed that RUNX2 was overexpressed in breast, esophageal, kidney, lung, and thyroid cancerous tissues and significantly downregulated in liver and prostate cancerous tissues and that RUNX2 and MGP expression exhibited a significant inverse correlation in bladder and lung cancers and a positive correlation in bile duct and head and neck cancers. This evidence concerns the gene RUNX2 and lung cancer.